Ignite Creation Date:
2025-12-24 @ 5:28 PM
Ignite Modification Date:
2026-02-03 @ 9:17 PM
Study NCT ID:
NCT04118868
Status:
UNKNOWN
Last Update Posted:
2022-10-12
First Post:
2019-10-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
Sponsor:
Sorrento Therapeutics, Inc.
Organization: